Fig. 5.

Expression of a DN mutant IGF-IR in GD fibroblasts can block the effects of GD-IgG on T-cell chemoattractant activity (A) and IL-16 (■) and RANTES (□) protein expression (B). Confluent cultures of fibroblasts from a patient with GD were transiently transfected with a plasmid containing the dominant-negative mutant IGF-IR designated 486/STOP or with empty vector (as control). Cultures were then treated with GD-IgG (100 ng/ml) or nothing (control) for 24 h. Media were collected and analyzed for T-cell migratory activity without (■) or with either anti-IL-16 (□) or anti-RANTES (▨) neutralizing antibodies (5 μg/ml) or for IL-16 and RANTES protein expression. The migratory data are expressed as a percentage compared with unstimulated (random) migration, which is designated 100%. *, statistically different migration in the presence of neutralizing antibodies (A) or protein production (B) at the 5% confidence level. [Reprinted from Pritchard J, Han R, Horst N, Cruikshank WW, and Smith TJ (2003) Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 170:6348–6354. Copyright © 2003 The American Association of Immunologists, Inc. Used with permission.]